J Med Assoc Thai 2005 Jun;88 Suppl 1:S12-20
Division of Endocrinology, Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Maha Chakri Sirinthorn Medical Center, Nakhon-Nayok 26120, Thailand.
Maturitas 2008 Jun 24;60(2):170-6. Epub 2008 Jun 24.
Department of Family Medicine, Eulji University School of Medicine, Jung-Gu, Daejeon, Republic of Korea.
Background: High bone turnover, with bone resorption exceeding bone formation, is a major mechanism of postmenopausal osteoporosis. Therefore, inhibition of bone resorption is a rational approach for the prevention of bone loss. The objective of the current study was to determine the short-term efficacy of once-weekly low-dose alendronate in the prevention of bone loss, via bone turnover markers, in early postmenopausal Korean women with moderate bone loss. Read More
Bone 2001 Jan;28(1):108-12
Bone and Cartilage Metabolism Unit, University of Liège, Liège, Belgium.
The present study describes the biological effects of risedronate, a pyridinyl bisphosphonate, on bone and assesses the safety and tolerability of risedronate when given at high doses, with or without calcium, to postmenopausal women with spinal osteoporosis. This single-center descriptive, double-blind, placebo-controlled, randomized, parallel group study included 32 postmenopausal white women with at least one radiographically confirmed vertebral compression fracture. Patients were randomized to one of four different dose regimen groups: (i) R-P, risedronate 20 mg/day for 14 days, followed by placebo for 42 days; (ii) R-CP-P, risedronate 20 mg/day for 14 days, followed by elemental calcium 1000 mg/day and placebo for 14 days, then by placebo for 28 days; (iii) R-CP-R-CP, risedronate 20 mg/day for 7 days, followed by elemental calcium 1000 mg/day and placebo for 21 days, then risedronate 20 mg/day for 7 days, and finally elemental calcium 1000 mg/day and placebo for 21 days; and (iv) P, placebo for 56 days. Read More
Clin Ther 2007 Sep;29(9):1937-49
Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Background: Randomized clinical trials have shown that risedronate reduces the risk for both ver- tebral and nonvertebral fractures in postmenopausal women with osteoporosis (bone mineral density [BMD] T-score, <-2.5). If left untreated, osteopenia (T-score, between -1 and -2. Read More
Calcif Tissue Int 2008 Aug 14;83(2):81-4. Epub 2008 Jun 14.
Division of Clinical Biochemistry, Institute of Medical and Veterinary Science, SA Health, Adelaide, South Australia, Australia.
This study was conducted to compare the suppressive effects of calcium carbonate and calcium citrate on bone resorption in early postmenopause. Calcium citrate is thought to be better absorbed. We therefore tested the hypothesis that calcium as citrate is more effective than calcium as carbonate in suppressing parathyroid hormone (PTH) and C-terminal telopeptide. Read More